John Libbey Eurotext

Médecine thérapeutique / Pédiatrie


Acute lymphoblastic leukemia in children Volume 22, issue 2, Avril-Mai-Juin 2019


  • Figure 1
  • Figure 2


1 Hôpital Armand Trousseau, Service d’Hématologie-Immunologie Pédiatrique, 26 avenue du Dr Arnold Netter, 75012 Paris
2 Hôpital Robert Debré, Service d’hématologie-immunologie pédiatrique, Boulevard Sérurier, 75019 Paris
* Correspondance

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. The identification of effective drug combination through collaborative international clinical trial has resulted in a steady improvement in treatment outcome. The identification of biological variables predictive of outcome and their use in stratifying treatment led to reduce the relapse risk. The current objectives are twofold; to improve the outcome for the significant minority of patients who relapse (with the development of target therapy and CAR-T cells) and to reduce the excessive drug toxicity (but maintain a high cure rate) for subgroups of patients with excellent outcome.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License